Ixazomib as treatment for pyoderma gangrenosum associated with IgA smoldering multiple myeloma

Ann Hematol. 2022 Feb;101(2):441-442. doi: 10.1007/s00277-021-04524-w. Epub 2021 Apr 15.

Authors

David Alvarez Cespedes¹, Stephanie M Gallitano², Divaya Bhutani³

Affiliations

¹ Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA.
² Department of Dermatology, Columbia University Irving Medical Center, New York, NY, USA.
³ Department of Medicine, Division of Hematology and Oncology, Columbia University Irving Medical Center, 161 Fort Washington Ave, New York, NY, 10032, USA. db3203@cumc.columbia.edu.

PMID: 33860355
DOI: 10.1007/s00277-021-04524-w

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Antineoplastic Agents / therapeutic use*
Boron Compounds / therapeutic use*
Glycine / analogs & derivatives*
Glycine / therapeutic use
Humans
Immunoglobulin A / analysis
Male
Pyoderma Gangrenosum / complications
Pyoderma Gangrenosum / drug therapy*
Smoldering Multiple Myeloma / complications
Smoldering Multiple Myeloma / drug therapy*

Substances

Antineoplastic Agents
Boron Compounds
Immunoglobulin A
ixazomib
Glycine